2013
DOI: 10.1371/journal.pone.0078538
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review

Abstract: BackgroundIntravitreal agents have replaced observation in macular edema in central (CRVO) and grid laser photocoagulation in branch retinal vein occlusion (BRVO). We conducted a systematic review to evaluate efficacy and safety outcomes of intravitreal therapies for macular edema in CRVO and BRVO.Methods And Findings: MEDLINE, Embase, and the Cochrane Library were systematically searched for RCTs with no limitations of language and year of publication. 11 RCTs investigating anti-VEGF agents (ranibizumab, beva… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
92
1
12

Year Published

2015
2015
2018
2018

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 102 publications
(105 citation statements)
references
References 38 publications
(199 reference statements)
0
92
1
12
Order By: Relevance
“…Pielen et al conducted a systematic review regarding "Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion" [1] . For both, intravitreal steroids and anti-VEGF agents, efficacy could be shown in randomized controlled trials.…”
Section: Efficacymentioning
confidence: 99%
See 3 more Smart Citations
“…Pielen et al conducted a systematic review regarding "Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion" [1] . For both, intravitreal steroids and anti-VEGF agents, efficacy could be shown in randomized controlled trials.…”
Section: Efficacymentioning
confidence: 99%
“…Intravitreal anti-VEGF agents target the macular edema and resolution may lead to visual improvement. The sooner the macular edema is treated, the better is the response and prognosis for the patient [1,2] . Morphological changes (macular edema) occur before functional impairment (visual acuity), so close monitoring of patients is warranted after initial anti-VEGF therapy to treat as soon macular edema reoccurs [1,3] .…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…[1][2][3][4] Dexamethasone is one of the most potent corticosteroids, with an anti-inflammatory activity that is sixfold greater than that of triamcinolone and 30-fold greater than cortisol. 5,6 In the dexamethasone implant, the active drug is dispersed through a biodegradable copolymer of lactic acid and glycolic acid (PLGA), forming a matrix structure (Novadur, Allergan Inc). 7 Dexamethasone intravitreal implants (DEX implants) can both reduce the risk of further vision loss and increase the chances of improving visual acuity in eyes with macular edema after BRVO or CRVO.…”
Section: Introductionmentioning
confidence: 99%